P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR –Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape
Journal of Clinical Oncology · 10.11.2026 · 44 (32) · 3163-3173
DOI: 10.1200/jco-26-00556 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2026. Verfasst von Federico Monaca und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Mutation. Die Arbeit nennt 71 Literaturangaben.
Abstract (Originalsprache)
PURPOSE A structure-function classification has defined epidermal growth factor receptor ( EGFR ) P-loop/αC-helix compressing (PACC) mutations and exon 20 insertions (ex20ins) as distinct subsets of kinase domain EGFR alterations. Lung cancers harboring those mutations display reduced sensitivity to EGFR tyrosine kinase inhibitors (TKIs) currently approved for EGFR classical sensitizing mutations and have often been managed with chemotherapy. METHODS This narrative review describes structural biology, clinical trial data, and real-world evidence on PACC and ex20ins EGFR -mutant non–small cell lung cancer, with a focus on current treatment options, emerging resistance mechanisms, and the potential treatment sequencing. RESULTS For EGFR PACC variants such as G719X, S768I, E709X, and L747X, second-generation TKIs such as afatinib provide the most consistent activity, whereas common-plus-PACC compound mutations often derive greater benefit from third-generation TKIs, including osimertinib. Emerging mutant-selective inhibitors, including firmonertinib and enozertinib, are now being explored as dedicated options for PACC mutations. For EGFR ex20ins, amivantamab and mutant-selective TKIs such as sunvozertinib, zipalertinib, and firmonertinib have demonstrated clinically meaningful activity, with WU-KONG28 establishing first-line superiority of sunvozertinib over platinum-pemetrexed. Across both these subsets, resistance remains heterogeneous, encompassing on-target mutations, including C797S and E709K, as well as MET and other bypass track pathways. CONCLUSION EGFR PACC and ex20ins are established subgroups of kinase domain mutations, distinct from classical mutations, due to structure and responsiveness to available TKIs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, United Kingdom.
- Department of Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston.
- Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
- Oncology Department, University Hospital Geneva, Geneva, Switzerland.
- Division of Cancer Sciences, The University of Manchester, Manchester, United Kingdom.
ORCID-Profile: Federico Monaca, Igor Randulfe, John V Heymach, Caicun Zhou, Alfredo Addeo, Xiuning Le, Raffaele Califano
Zitieren
APA
Monaca, F., Randulfe, I., Heymach, J. V., Zhou, C., Addeo, A., Le, X., & Califano, R. (2026). P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR –Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape. Journal of Clinical Oncology, 44(32), 3163-3173. https://doi.org/10.1200/jco-26-00556
Vancouver
Monaca F, Randulfe I, Heymach JV, Zhou C, Addeo A, Le X, et al. P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR –Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape. Journal of Clinical Oncology. 2026;44(32):3163-3173. doi:10.1200/jco-26-00556
BibTeX
@article{Monaca2026,
author = {Monaca, Federico and Randulfe, Igor and Heymach, John V and Zhou, Caicun and Addeo, Alfredo and Le, Xiuning and Califano, Raffaele},
title = {P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR –Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {32},
pages = {3163--3173},
doi = {10.1200/jco-26-00556}
}
EUVIMED